Targacept Announces Designation Of Lead Compound In Smoking Cessation Program
May 15th 2008Drug InformationSmoking / Quit Smoking
Targacept, Inc. (NASDAQ:TRGT), a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR Therapeutics (TM), announced the designation of a lead compound in its smoking cessation program, triggering a $500,000 milestone payment under its alliance agreement with GlaxoSmithKline (GSK).
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
